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Background: This study was performed to determine if a chemotherapy-induced apoptosis assay (MiCK) could
predict the best therapy for patients with ovarian cancer.
Methods: A prospective, multi-institutional and blinded trial of the assay was conducted in 104 evaluable ovarian
cancer patients treated with chemotherapy. The MiCK assay was performed prior to therapy, but treating physicians
were not told of the results and selected treatment only on clinical criteria. Outcomes (response, time to relapse,
and survival) were compared to the drug-induced apoptosis observed in the assay.
Results: Overall survival in primary therapy, chemotherapy naïve patients with Stage III or IV disease was longer if
patients received a chemotherapy which was best in the MiCK assay, compared to shorter survival in patients who
received a chemotherapy that was not the best. (p < 0.01, hazard ratio HR 0.23). Multivariate model risk ratio
showed use of the best chemotherapy in the MiCK assay was the strongest predictor of overall survival (p < 0.01) in
stage III or IV patients. Standard therapy with carboplatin plus paclitaxel (C + P) was not the best chemotherapy in
the MiCK assay in 44% of patients. If patients received C+ P and it was the best chemotherapy in the MiCK assay,
they had longer survival than those patients receiving C + P when it was not the best chemotherapy in the
assay (p = 0.03). Relapse-free interval in primary therapy patients was longer if patients received the best
chemotherapy from the MiCK assay (p = 0.03, HR 0.52). Response rates (CR + PR) were higher if physicians used
an active chemotherapy based on the MiCK assay (p = 0.03).
Conclusion: The MiCK assay can predict the chemotherapy associated with better outcomes in ovarian cancer
patients. This study quantifies outcome benefits on which a prospective randomized trial can be developed.Introduction
Epithelial ovarian cancer is responsive to several che-
motherapeutic drugs. However, there is considerable
variability in individual response to these drugs in com-
bination or as single agents. Oncologists have wanted to
develop an assay that can predict response to chemo-
therapy drugs and combinations to allow individualized
cancer therapy.
The issue of predictive testing for choosing chemother-
apy for cancer patients is of very high interest. The MiCK
assay for drug-induced apoptosis is a non-genomic test* Correspondence: bestchemo@gmail.com
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reproduction in any medium, provided the orthat is in national trials in a number of different
tumors.
Assays for chemotherapy resistance have been devel-
oped in the past, but their application in ovarian cancer
has been of limited usefulness [1]. NCCN acknowledges
that some institutions do use these tests in patients, but
their general use is not guideline-approved [2].
A drug-induced apoptosis assay, the microculture-
kinetic test (MiCK), has been developed [3] and tested
with success in acute myelocytic leukemia [4,5]. The
basis of this assay is the ability of a drug to rapidly in-
duce apoptosis in cancer cells in short-term culture
(48 hours) without a necessity for tumor cell growth. In
addition to testing in AML, it has been undergoing test-
ing in solid tumors including breast cancer [6],td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumors and hematologic malignancies (the results of a
non-blinded trial are in press, Cancer, 2012). These
results indicate that the MiCK assay is more predictive
of response and survival than almost all currently avail-
able genomic tests (probably because there are so many
mutations, and epigenetic changes in every cancer, most
usually different between cancers of similar histologic
type, and often differing between metastases in the same
patient).
We report here the results of a multi-center, prospect-
ive, non-randomized, and physician-blinded study of the
MiCK assay in patients with ovarian cancer.
Methods
Patients with epithelial ovarian cancer of any stage, pri-
mary or recurrent, were eligible. Sterile tumor specimens
(minimum 250 mg but optimally with >1.0 cm3 of viable
tumor tissue) were placed into sterile DiaTech transport
media, and sent via FedEx to the DiaTech Oncology la-
boratory, Montreal, Canada.
Tumor cell purification
Within 24 to 48 hours of collection, the specimen was
minced, digested with 0.25% trypsin and 0.08% DNase
for 1–2 hours at 37 degrees Celsius, and then filtered
through a 100 micrometer cell strainer. Tumor cells
were purified by a proprietary method which included
density gradient centrifugation, and incubation with a
series of antibody-coated beads to allow only viable
tumor cells to remain. The pathologist confirmed that
the remaining cells in the assay were at least 90% viable
ovarian cancer cells. The final cell suspension was plated
into a 96-well half-area plate, 120 microliter aliquot per
well. The plate was incubated overnight at 37 degreesTable 1 Drug-Induced Apoptosis in the MiCK Assay
Drug # 0f Patients Mean Ass
Carboplatin 69 1.8
Paclitaxel 73 2.2
Carboplatin + Paclitaxel 99 2.9
Cisplatin 45 2.7
Gemcitabine 41 0.9
Cisplatin +Gemcitabine 82 2.5
Docetaxel 9 2.1
Topotecan 67 1.5
4hydroxycyclophosphamide 20 2.9
Doxorubicin 4 3.3
Liposomal doxorubicin 65 1.0
Epirubicin 9 3.2
Albumin-bound Paclitaxel 4 0.7Celsius with 5% carbon dioxide humidified atmosphere.
5x104 to 1.5x105 cells were seeded per well depending
on the cell volume to give adequate well-bottom
coverage.
Human JURL-MK2 chronic leukemia in blast crisis
cell line (DSMZ, Germany) was used as a positive con-
trol for MiCK assays performed with patient tumor cells.
RPMI-1640 medium without phenol red was used for all
cultures. It was supplemented with 10% fetal bovine
serum, 100 units/mL of penicillin, and 100 micrograms/
mL of streptomycin. Cell counts and viability were eval-
uated by trypan blue dye exclusion.
Each tumor cell preparation was reviewed by a path-
ologist using a hematoxylin/eosin stained cytospin prep-
aration to confirm the presence of malignant cells
consistent with an ovarian carcinoma primary. If there
was an adequate number of cells available, immunocyto-
chemical stains including CK, CA125, calretinin and Ki-
67 were performed to add supportive evidence of an
ovarian origin as well as mitotic activity. The cell sus-
pensions were purified repetitively until at least 90% pur-
ity was obtained. Suspensions with under 90% purity
were not tested in the MiCK assay.
MiCK assay for apoptosis
The MiCK assay procedure was adapted from the
method described previously [3,4]. After overnight incu-
bation, chemotherapy drugs were added in the wells of
the 96-well plate in 5 microliter aliquots at various con-
centrations. Single and combination regimens were
tested, as seen in Table 1.
Three concentrations of each drug or combination
were tested based on the distribution of standard drug
dose in total body water as the mid-range concentration,
with another concentration above and below the mid-ay KU Minimum Assay KU Maximum Assay KU
0 12.4
0 9.7
0.7 8.2
0 9.1
0 3.4
0 11.4
0 3.4
0 6.8
0 15.4
0.4 6.9
0 5.3
0.4 7.7
0 1.3
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was incubated for 30 min at 37 degrees Celsius into a
5% carbon dioxide humidified atmosphere incubator.
Each well was then overlayed with mineral oil, and the
plate was placed into the incubator chamber of a micro-
plate spectrophotometric reader (BioTek instruments).
The optical density at 600 nanometers was read and
recorded every 5 minutes over a period of 48 hours. Op-
tical density increases, which correlate with apoptosis,
were converted to kinetic units (KU) of apoptosis by a
proprietary software ProApo with a formula described
previously [3,4] and were correlated with patient out-
comes. Spontaneous apoptosis was controlled for using
control wells containing patient tumor cells without
drugs. Active apoptosis was indicated as > 1.0 KU.
Treatment of patients
This study was a prospective multi-institutional blinded
trial. It was non-randomized, and thus was an observa-
tional study. MiCK assay results were obtained before
any therapy was initiated. MiCK assay results were never
transmitted to physicians. Physicians treated patients
with the physicians’ own choice of drugs as they deemed
clinically indicated. Tumor responses were measured by
RECIST criteria every 3 months. Patients were evaluated
for response, time to recurrence after assay and disease-
specific survival after assay. The clinical evaluations of
response, time to recurrence and survival were then
compared to the in vitro MiCK assay drug-induced
apoptosis that had been determined before chemother-
apy was initiated.
Statistical evaluation
The primary goal of the study was to compare MiCK
assay results with overall survival in all patients studied.
We also evaluated the subset of patients with
chemotherapy-naïve stage III and IV ovarian cancer re-
ceiving primary therapy for overall survival, response
rate, and recurrence-free survival. Data were imported
into SAS/JMP (JMP Version 7 for Windows [8]) for ana-
lysis. If a sample had multiple doses of the same drug,
then the dose with the highest value was assigned to the
drug. SAS/JMP was used to calculate summary statisticsTable 2 Multivariate Analysis of Overall Survival
Term Risk Ratio
Age 0.86
Debulking (sub = 0 optimal = 1) 0.36
Drug (non Best = 0 Best = 1) 0.21
Ln ca 125 1.18
Size of residual (none = 0 some = 1)) 0.59
Cox proportional hazards model for 61 evaluable patients with stage III or IV primar
Patients (n = 3) with no debulking were omitted. CL, confidence limit of risk ratio.and perform statistical analysis (see Table 2). Compari-
sons between drugs were made by subtracting one drug’s
KU value from another drug’s KU value on a matched
sample basis. The nonparametric Wilcoxon test [9] was
then used to test for a statistical difference. All tests
were two-tailed. Multivariate analysis was performed
using the Cox proportional hazards model [10]. In order
to account for multiplicity, MULTTEST (SAS 9.2) was
used to compute adjusted p-values by the Hochberg,
Holm and false discovery rate methods [11-13]. Statisti-
cally significant results remained significant at the 0.05
level.
Definition of best chemotherapy
The best chemotherapy was defined as any single drug
or drug combination with the highest KU +/− 0.57 KU
in an individual patient’s MiCK assay. Several different
drugs or combinations could all be considered a best
chemotherapy if they were all within 0.57 KU of each
other. The 0.57 KU cut-off was based on the standard
deviation 0.57 KU using analysis of variance in tests of
replicate tumor samples in the MiCK assay.
Investigational review board approval
IRB approval was obtained and monitored by the West-
ern IRB in Seattle, Washington. Each patient had given
voluntary informed consent in writing prior to submis-
sion of tumor specimen for MiCK analysis. The trial was
registered at clinicaltrials.gov at study NCT00531388.
Results
Patients studied
Specimens were submitted from 210 patients between
May, 2006 and September, 2010. Of these, 60 were un-
successful due to insufficient number of viable cancer
cells (40% of the 60), spontaneous necrosis in transit
(17%), or delays in transit. Recent experience since 2009
has demonstrated over 75% successful cultures as these
problems have been resolved by better instructions to
surgeons and pathologists.
The remaining 150 patients had tumor submitted and
analyzed, and were evaluable for patterns of in vitro
assay of drug effects on ovarian cancer cells (see resultsLower CL Upper CL p-value
0.05 13.57 0.92
0.07 1.72 0.19
0.05 0.65 < 0.01
0.08 19.29 0.90
0.12 2.24 0.45
y disease. Risk ratios calculated per change in regressor over entire range.
Table 3 Patient Characteristics
All Primary Stage III & IV
Patients % Patients %
Number of patients 104 100 77 100
Stage
I 5 4.8 %
II 2 1.9 %
III 67 64.4 % 67 87.0 %
IV 10 9.6 % 10 13.0 %
Recurrent 20 19.2 %
Debulking
No 5 4.8 % 3 3.9 %
yes optimal 79 76.0 % 58 75.3 %
yes suboptimal 20 19.2 % 16 20.8 %
Size of residual
0 56 56.6 % 39 52.7 %
<1 cm 18 18.2 % 15 20.3 %
>1 cm 25 25.3 % 20 27.0 %
Lines of therapy before MiCK
0 87 83.7 % 77 100 %
1 4 3.8 %
2 3 2.9 %
3 10 9.6 %
Preoperative CA125
mean 1714.5 2147.6
median 384.5 510.5
range 4 - 26,728 4 - 26,728
missing 13 11
Age
mean 59.4 59.7
median 60 60
range 35 - 86 37 - 86
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outcome data since they did not return after discharge
postoperatively, despite extensive efforts to obtain that
data. Nearly all of those patients also declined postopera-
tive chemotherapy. 29 of the remaining 133 patients
either did not receive chemotherapy (24 patients),
received chemotherapy for which there is no assay (3
patients receiving EC145 on a clinical trial, bleomycin,
or rituximab plus CHOP), or had therapy that could
not be matched to the MiCK assay results because of
too few assays (2 patients), leaving 104 patients who
received chemotherapy and were evaluable for clinical
correlations with assay results.
Of the 104 patients who received chemotherapy, 77
were stages III or IV primary treatment patients. Table 3
describes the patient characteristics of all 104 patients
and those with chemotherapy-naïve stage III or IV can-
cer. The tumor histologies of all patients and of the stage
III-IV patients, respectively, were papillary-serous 66/48;
ovarian adenocarcinoma (not otherwise specified) 23/22;
endometroid 6/2; clear cell 2/2; mucinous 1/1; and
mixed + combined + other 6/2. Of the 104 patients, 98
had documented survival data and are described in
Figure 1.
In vitro apoptosis results
Table 1 lists the results of testing with each of the drugs
and/or combinations in 150 patients. Since the yield of
tumor cells varied, not all patients had each drug and
combination tested. The most active compounds
included the combination of carboplatin and paclitaxel,
and the single agents 4-hydroxy-cyclophosphamide (the
activated form of cyclophosphamide), epirubicin, doce-
taxel, and cisplatin.
Analyses compared the results in individual patients
using two drug combinations of carboplatin plus pacli-
taxel versus carboplatin as a single drug, and versus
paclitaxel as a single drug (n = 103). In the entire patient
study, combination of carboplatin plus paclitaxel was
significantly more effective in producing apoptosis than
carboplatin alone (p < 0.0001) or paclitaxel alone
(p < 0.0001). However, in individual patient tests, com-
pared to carboplatin plus paclitaxel, either carboplatin or
paclitaxel as single drugs gave more apoptosis than the
combination in 25 out of 90 evaluations (28%), and sin-
gle drugs gave results equal to the combination in 8 out
of 90 patients (9%).
Also, the results of cisplatin plus gemcitabine were
compared to cisplatin as a single drug or gemcitabine as
a single drug (n = 55). The combination of cisplatin plus
gemcitabine was significantly better in producing apop-
tosis overall compared to gemcitabine alone (p < 0.0001).
In individual patient assays, however, compared to the
combination of cisplatin plus gemcitabine, the singledrugs gave more apoptosis than the combination in 14
out of 44 patients (32%) and the single drugs produced
apoptosis equal to the combination in 8 out of 44
patients (18%). No patients were treated clinically with
these single agents.
Correlations of MiCK apoptosis results with overall
survival in all patients studied
Because all ovarian cancer patients were eligible per
protocol for MiCK assay, this section presents the
results in all patients studied. The overall survival of all
98 evaluable patients treated with chemotherapy was
compared to the results of the MiCK apoptosis assay. In
this comparison, the 60 patients who were treated with
the best chemotherapy in the MiCK assay had a superior
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Figure 1 Overall survival of patients with stage 3 or 4 primary
disease without prior chemotherapy. Red line, 44 patients
receiving a best chemotherapy. Blue line, 29 patients receiving
non-best chemotherapy. P < 0.01.
Salom et al. Journal of Translational Medicine 2012, 10:162 Page 5 of 8
http://www.translational-medicine.com/content/10/1/162overall survival compared to the 38 patients who
received a non-best chemotherapy (p = 0.003 by log rank
analysis). Median survival was over 45 months for
patients who received the best chemotherapy compared
to 25 months for patients who received a non-best
chemotherapy. The primary goal of the study was met.
In addition, of the patients treated with the best
chemotherapy, 53.3% recurred, compared to 76.3% re-
currence in patients who received a non-best chemo-
therapy (p = 0.02).Evaluation of patients with chemotherapy-naïve stages III
or IV primary therapy
Overall survival
This section presents the results in the more homoge-
neous subset of patients, those with chemotherapy-naïve
stages III or IV most of whom had received tumor
debulking (Table 3). No patient had received neoadju-
vant therapy. The overall survival of all stages III or IV
patients with primary disease was 51.2% +/− 10.7% at
42 months (this is comparable to the results of GOG
protocol 182 [14], GOG protocol 218 [15], and AGO-
OVAR 9 [16]).
In the chemotherapy-naïve stage III or IV ovarian can-
cer patients (73 with fully evaluable survival data),
patients treated with the best chemotherapy in the
MiCK assay had a superior survival compared to
patients treated with a non-best chemotherapy (Figure 1,
p < 0.01). The hazard ratio for death in patients receiving
the best chemotherapy was 0.23 (95% confidence inter-
val 0.06 to 0.67). Median survival was over 45 months
for patients who received the best chemotherapy com-
pared to 25 months for patients who received a non-best
chemotherapy.In order to exclude the possibility that there was an
accidental selection of more favorable patients into pre
the best chemotherapy group, a multivariate analysis was
performed in the stage III and IV patients with primary
therapy who had complete data to determine if the
MiCK assay results were predictive of survival compared
to other prognostic variables in prior analyses (Table 2).
The multivariate Cox proportional hazard model showed
that use of the best chemotherapy in the MiCK assay
was the strongest predictor of overall survival. The esti-
mated hazard risk ratio (relative risk) for death if a pa-
tient received the best chemotherapy was 0.21 (95%
confidence interval 0.05 to 0.65, p < 0.01). Although
prior studies have indicated that optimal debulking and
having less residual disease were favorable prognostic
factors, those factors were less prognostic when the
MiCK assay results were considered in the same
analysis.
In order to confirm that the MiCK assay was predict-
ive in patients with the most optimal prognostic charac-
teristics, we analyzed patients with stage III and IV
disease, no prior chemotherapy, optimally debulked with
no residual disease. Of those patients, 24 were treated
with the best therapy as analyzed in the MiCK assay,
and 14 were treated with drugs that were not the best in
the assay. Median survival I those treated with the best
drugs was over 42 months, compared to median survival
of only 25 months in those who received chemotherapy
that was not the best (p < 0.01).
Recurrence-free interval
In the 72 patients with fully evaluable recurrence data
who had chemotherapy-naïve stage III or IV primary
disease, the recurrence-free interval of patients treated
with the best chemotherapy was longer compared to
patients treated with a non-best chemotherapy (Figure 2,
p = 0.03). The hazard ratio for recurrence in patients re-
ceiving the best chemotherapy was 0.52 (95% confidence
interval 0.28 to 0.96). Median recurrence-free interval
was 16 months in patients receiving the best chemother-
apy versus 6 months for patients receiving a non-best
chemotherapy.
A multivariate analysis was performed in these
patients with complete data to determine if the MiCK
assay results were predictive of recurrence-free interval.
Use of the best chemotherapy in the MiCK assay gave a
hazard ratio for recurrence of 0.60, but this was of only
marginal statistical significance (95% confidence interval
0.31 to 1.16, p = 0.13).
Correlations of MiCK apoptosis results with response
We next evaluated whether or not there was a relation-
ship between apoptosis in the assay compared to clinical
response. In patients with chemotherapy-naïve stage III
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Figure 2 Recurrence-free interval of patients with stage 3 or 4 primary disease without prior chemotherapy. Red line, 43 patients
receiving a best chemotherapy. Blue line, 29 patients receiving non-best chemotherapy. P = 0.03.
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apy that had high apoptosis > 2 KU, 90% of the patients
had a complete or partial response, compared to 74% re-
sponse if the physicians used chemotherapy that had
apoptosis </= 2 KU (p =0.10). If patients had received
chemotherapy with any apoptosis >1.14 KU, 87% had
complete or partial response, compared to only 40.0% of
patients who received less active chemotherapy </=
1.14 KU (p = 0.03). The overall response rate for all
stage III or IV patients was 83.3%.
Can the MiCK assay improve standard therapy with
carboplatin plus pactlitaxel?
In the 51 patients with stage III or IV disease who
received standard therapy with carboplatin + paclitaxel
(C + P), we studied whether C+P was best therapy in
the MiCK assay. In 28 of 51 (56%), C + P was the best
chemotherapy based on the assay. It was not the best
chemotherapy in 44%, and the most usual better choice
by the MiCK assay was gemcitabine plus cisplatin in 10
(43%). When physicians used C+P, time to recurrence
was significantly longer if it was the best therapy com-
pared to patients in whom it was a non-best therapy
(p = 0.03); and overall survival was marginally longer if
C + P was the best therapy versus if C + P was a non-best
therapy (p = 0.1) with 88% survival at 30 months if C + P
was the best therapy, versus 20% if it was a non-best
therapy (based on Kaplan-Meier curves).
Is the MiCK assay just a prognostic variable?
In order to test if the maximum degree of apoptosis was
prognostic of overall survival without considering
whether the patient received the best or a non-best
chemotherapy, a Cox proportional hazards model was
performed. In all patients receiving chemotherapy, apop-
tosis was not correlated to survival (p = 0.40). In patients
with stage III or IV primary disease, apoptosis was not
correlated to survival (p = 0.24). Survival was onlycorrelated with apoptosis if the physician used the best
chemotherapy regimen from the MiCK assay (Figure 1).
Discussion
This prospective, multi-institutional blinded study
demonstrated a significant correlation between using the
best chemotherapy regimen as assessed in the MiCK
assay and overall survival both in all ovarian cancer
patients studied, and in the more homogeneous subset
of patients with chemotherapy-naïve stage III or IV pri-
mary disease. Using the best chemotherapy regimen
based on the MiCK assay also correlated with relapse-
free interval. If the physicians used a chemotherapy regi-
men with higher activity in the MiCK assay, response to
therapy was higher. This suggests in this non-
randomized observational trial that the MiCK assay can
help guide selection of more active chemotherapy in
ovarian cancer patients. Based on this hypothesis gener-
ating study, subsequent randomized validation trials will
help further elucidate the benefits of using the MiCK
assay to select appropriate therapy for these patients.
This study justifies such a randomized trial, and quanti-
fies the benefits in outcomes on which a randomized
study can be developed (for power determinations and
study size requirements). Such a randomized prospective
trial should compare standard postoperative therapy of
patients with stages III and IV epithelial ovarian cancer,
versus therapy directed by the best results in the MiCK
assay. Appropriate stratifications would include extent of
debulking, amount of residual disease, stage, age, and
preoperative CA125. Numbers of patients needed to
treat would be determined by participating statisticians
based on primary and secondary goals.
A review by the American Society of Clinical Oncol-
ogy (ASCO, 1) has found prior chemosensitivity and
chemoresistance assays to be insufficiently robust in pre-
dicting outcomes, and has not recommended their rou-
tine use. This MiCK assay was not reviewed in any of
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conclusions that “because the in vitro analytic strategy
has potential importance, participation in clinical trials
evaluating these technologies remains a priority.” This
study represents such a trial that can contribute to sub-
sequent reviews by that ASCO committee and other
organizations. This study also represents evidence on
which future validation and utility trials can be based.
In contrast to prior chemotherapy resistance assays,
the MiCK assay is different. The MiCK assay measures
direct in vitro cell killing (rather than measuring only
survival of cells), studies only cancer cells (compared to
mixed host and cancer cells), requires no in vitro growth
of tumor cells (compared to assays requiring growth of
cells, which measures only a subset of cancer cells cap-
able of growth in vitro), gives results based on multi-
point analyses (every 5 minutes for 48 hours) rather
than just a single endpoint [17], and has results available
within 72 hours of biopsy (rather than 3–4 weeks).
The ability to identify drugs which are active in the
clinical therapy of ovarian cancer suggests that this assay
may also be able to play a role in drug development.
The assay might be used to study new drugs pre-
clinically (2 such trials have been completed, unpub-
lished data), to evaluate if drugs known to be active in
other cancers may also have activity in ovarian cancer,
and to identify which patients are most likely to respond
in clinical trials. This would allow phase II and phase III
trials to be focused on patients with the highest chance
of improvement, reducing time needed to conduct a
clinical trial and increasing the probability of finding ef-
fective new drugs. The MiCK assay may also be able to
give pharmaceutical companies indications of which
approved drugs may be more effectively combined with
investigational agents, thus prioritizing clinical trials for
more rapid approval by regulatory agencies.
The assay also showed that in some patients (approxi-
mately 1/3 to 1/2), single agents were as effective in killing
ovarian cancer tumor cells in vitro as standard combin-
ation therapies. If confirmed clinically, the MiCK assay
may be useful to physicians in individualizing therapy,
especially in patients at increased risk of toxicity from
combination drug treatments or patients fearful of side
effects of combination therapy. Single agent chemother-
apy has been found equivalent to combination chemo-
therapy in some trials [18,19] but not others [20,21].
Since the MiCK assay indicates which drugs are asso-
ciated with improved survival, it is possible that use of
the assay may reduce healthcare costs by avoiding in-
active therapies. Results of studies [22] have been used
to model potential cost savings in care of cancer patients
in a large self-insured employer database. This study
indicated possible cost savings of 25 to 85% of
chemotherapy-associated expenses.Since this study initially had a high rate of unsuccess-
ful assays, education of participating sites about submis-
sion and processing procedures have been improved
which resulted in consistently higher success rates over
75%. Although the learning curve is very fast, the com-
pany which provides the test has improved its support of
centers using the assay so that inevaluable specimens are
less frequent.
In summary, use of the best chemotherapy regimen as
assessed in the drug-induced apoptosis MiCK assay cor-
related with overall survival in all ovarian cancer
patients, and in patients with chemotherapy-naïve stage
III or IV primary therapy patients with a hazard ratio for
death of 0.23. The assay is predictive of survival if physi-
cians use the best treatment based on the assay. Relapse-
free interval and response rate were also predicted by
the MiCK assay. Further studies of this predictive thera-
nostic bioassay are warranted.
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